Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilenya

- PMLiVE

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis

Approximately 2.5 million people worldwide are affected by the neurological disease

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Sandoz biosimilar receives EC approval to treat MS

Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe

- PMLiVE

Sanofi and Ad Scientiam partner to assess MS disability progression

The study will evaluate the ability of MSCopilot to identify early signs of disability worsening

- PMLiVE

Octopus clinical trial for progressive MS advances with new site in Wales

The Cardiff site is one of up to 30 sites that will eventually open across the UK as part of the trial

- PMLiVE

Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

- PMLiVE

Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement

The FTC filed an antitrust lawsuit against Amgen earlier this year in a bid to block the transaction

- PMLiVE

Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

The disease-modifying therapy is approved to treat all indications covered by Tysabri

- PMLiVE

Study suggests self-reported information could help predict MS progression

Predicting MS progression could improve treatment and care outcomes for patients

- PMLiVE

TG signs $645m deal with Neuraxpharm to support international launch of MS antibody

Briumvi has already been approved in the US and EU for adults with relapsing forms of MS

- PMLiVE

UK experts and politicians meet to discuss challenges faced by progressive MS patients

Primary-progressive MS accounts for approximately 10-15% of multiple sclerosis cases

- PMLiVE

World Health Organization publishes updated essential medicines list

Three medicines that can delay or slow MS disease progression have been included in the EML

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links